Comparative Pharmacology
Head-to-head clinical analysis: CEPHRADINE versus KEFLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPHRADINE versus KEFLET.
CEPHRADINE vs KEFLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephradine is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Keflet (warfarin) inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of clotting factors II, VII, IX, and X in the liver.
250-500 mg orally every 6 hours; 500 mg to 1 g intramuscularly or intravenously every 6 hours. Maximum: 4 g/day.
500 mg orally every 12 hours for 10-14 days; for uncomplicated UTI: 250 mg orally every 12 hours for 7 days.
None Documented
None Documented
Terminal elimination half-life 0.5–1.5 hours (normal renal function); prolonged to 6–15 hours in severe renal impairment (CrCl <10 mL/min).
0.5-1 hour; prolonged in renal impairment (up to 20-30 hours in ESRD).
Primarily renal (≥90% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal (<10%).
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic